Is LIMN or MESO more undervalued in 2026?

CirclFi compares Liminatus Pharma, Inc. (LIMN) and Mesoblast Limited (MESO) using 13 institutional-grade valuation models. LIMN has a Quality of Company score of 3.5/10 while MESO scores 1.7/10.

Which is a better buy — LIMN or MESO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LIMN and MESO valuations compare?

LIMN at $0.16 and MESO at $15.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LIMN vs MESO Valuation Comparison 2026 — Intrinsic Value Analysis

LIMN

Biological Products, (No Diagnostic Substances)

Liminatus Pharma, Inc.

Quality

3.5

out of 10

Value Trap

—

Price

$0.16

Last close

Models

7/13

Active

MESO

Biological Products, (No Diagnostic Substances)

Mesoblast Limited

Quality

1.7

out of 10

Value Trap

—

Price

$15.40

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	LIMN Fair Value	LIMN Upside	MESO Fair Value	MESO Upside
Bayesian DCF	Intrinsic	$0.09	-45.0%	$3.91	-74.6%
Earnings Power Value	Intrinsic	—	—	$6.54	-57.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.02	-85.8%	$2.21	-85.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LIMN vs MESO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LIMN vs MESO — Which Stock Is More Undervalued?

LIMN scores higher with a 3.5/10 quality rating vs MESO's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Liminatus Pharma, Inc. (LIMN) and Mesoblast Limited (MESO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LIMN currently trades at $0.16 with a QOC of 3.5/10, while MESO trades at $15.40 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).